MK-1064

CAS No. 1207253-08-4

MK-1064( MK1064 | MK 1064 )

Catalog No. M10761 CAS No. 1207253-08-4

A potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 140 In Stock
10MG 230 In Stock
25MG 455 In Stock
50MG 644 In Stock
100MG 869 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MK-1064
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM.
  • Description
    A potent, selective, orally bioavailable Orexin 2 receptor (OX2R) antagonist with Ki/IC50 of 0.5/18 nM; displays >100-fold selectivity over OX1R; promotes sleep and increases both rapid eye movement (REM) and non-REM (NREM) sleep in rats and dogs without inducing cataplexy; also decreases ACTH levels in rats.Sleep Disorder Preclinical(In Vitro):MK-1064 (30?mg/kg, oral administration) promotes sleep in rodents selectively through OX2R in Wild-type mice.MK-1064 (30?mg/kg, oral administration, 5 days) reverses the struggle behavior induced by CNO pre-treatment in rats.MK-1064 (1-5 mg/kg, intravenous injection/oral administration) shows moderate oral bioavailability and clearance in rat, dog, and rhesus monkey.
  • In Vitro
    ——
  • In Vivo
    MK-1064 (30?mg/kg, oral administration) promotes sleep in rodents selectively through OX2R in Wild-type mice.MK-1064 (30?mg/kg, oral administration, 5 days) reverses the struggle behavior induced by CNO pre-treatment in rats.MK-1064 (1-5 mg/kg, intravenous injection/oral administration) shows moderate oral bioavailability and clearance in rat, dog, and rhesus monkey. Animal Model:Wild-type and OX2R knockout miceDosage:30 mg/kg Administration:Oral administration Result:Displayed active wake reduction accompanied by significant increases in SWS (slow-wave sleep) and REM (rapid eye movement) at time points up to 3.5?hours following treatment. Animal Model:Rat, dog, and rhesus monkey (Pharmacokinetics assay)Dosage:1, 2, 3, 5 mg/kg Administration:Oral administration (P.O.), intravenous injection (I.V.)Result:Pharmacokinetics profile of MK-1064.
  • Synonyms
    MK1064 | MK 1064
  • Pathway
    GPCR/G Protein
  • Target
    Orexin Receptor
  • Recptor
    OX2
  • Research Area
    Neurological Disease
  • Indication
    Sleep Disorder

Chemical Information

  • CAS Number
    1207253-08-4
  • Formula Weight
    461.9003
  • Molecular Formula
    C24H20ClN5O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(C1=CC(C2=CC(Cl)=CN=C2)=CN=C1C3=NC=CC=C3)NCC4=NC(OC)=C(OC)C=C4
  • Chemical Name
    [2,2':5',3''-Terpyridine]-3'-carboxamide, 5''-chloro-N-[(5,6-dimethoxy-2-pyridinyl)methyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Roecker AJ, et al. ChemMedChem. 2014 Feb;9(2):311-22. 2. Gotter AL, et al. Sci Rep. 2016 Jun 3;6:27147. 3. Grafe LA, et al. Neuroscience. 2017 Apr 21;348:313-323.
molnova catalog
related products
  • Almorexant hydrochlo...

    A dual Orexin receptor OX1/OX2 antagonist with Ki of 1.3/0.17 nM for hOX1/hOX2 respectively.

  • Seltorexant

    A potent, selective, orally active orexin-2 receptor (OX2R) antagonist with pKi of 8.0 and 8.1 for human and rat OX2R, respectively.

  • L-371,257

    L-371,257 is a competitive antagonist of oxytocin receptor with pA2 of 8.4 and Ki of 19 nM. L-371,257 shows a Ki of 3.7 nM for vasopressin receptor 1a.